Werewolf Therapeutics’ (HOWL) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a report issued on Wednesday morning, Marketbeat Ratings reports. They currently have a $8.00 target price on the stock.

HOWL has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research report on Wednesday. JMP Securities dropped their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research note on Tuesday, January 14th.

Werewolf Therapeutics Stock Performance

Werewolf Therapeutics stock opened at $1.20 on Wednesday. The company has a market capitalization of $53.48 million, a PE ratio of -0.78 and a beta of 0.37. The firm has a fifty day simple moving average of $1.35 and a two-hundred day simple moving average of $1.81. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics has a twelve month low of $1.03 and a twelve month high of $6.89.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. Research analysts expect that Werewolf Therapeutics will post -1.56 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors have recently made changes to their positions in the stock. D. E. Shaw & Co. Inc. purchased a new position in Werewolf Therapeutics in the fourth quarter worth approximately $26,000. Regal Investment Advisors LLC increased its holdings in shares of Werewolf Therapeutics by 88.1% in the 4th quarter. Regal Investment Advisors LLC now owns 27,204 shares of the company’s stock valued at $40,000 after acquiring an additional 12,745 shares during the period. XTX Topco Ltd acquired a new position in Werewolf Therapeutics in the 3rd quarter valued at $45,000. Levin Capital Strategies L.P. acquired a new position in Werewolf Therapeutics in the 4th quarter valued at $74,000. Finally, Jane Street Group LLC boosted its position in shares of Werewolf Therapeutics by 261.2% during the 4th quarter. Jane Street Group LLC now owns 54,713 shares of the company’s stock worth $81,000 after purchasing an additional 39,564 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.